A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
Status:
COMPLETED
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.